How to Dose Tirzepatide

Tirzepatide titration follows a fixed 2.5 mg ladder, escalating every 4 weeks from a 2.5 mg starter dose through 5, 7.5, 10, 12.5 and 15 mg once-weekly, as established in SURMOUNT-1 and SURMOUNT-2 [2][9]. This schedule is based on the pharmacokinetic half-life of tirzepatide (approximately 5 days) and allows sufficient time for receptor-level adaptation at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors before dose escalation. Body Pharm supplies tirzepatide in two multi-dose pens — a 30 mg pen and a 60 mg pen, both in a 3 mL cartridge. You set the dose directly on the dial in milligrams; the pen delivers the dialled mg regardless of its internal concentration, so there is no volume calculation and no click-counting to do. The concentration differs between the two pens (the 60 mg pen simply holds twice the drug in the same 3 mL) but it is not a number you dose against.

This guide covers the standard 2.5–15 mg titration ladder, how the dial maps to each step on Body Pharm pens, and when a dose is escalated or held, based on tolerability data from the SURMOUNT trials.

Key Takeaways

• Tirzepatide escalates in 2.5 mg increments every 4 weeks from 2.5 mg to a maximum of 15 mg weekly
• Body Pharm's 30 mg and 60 mg pens both dial the dose directly in milligrams from a 3 mL cartridge — no volume maths and no click-counting; the concentration is not something you dose against
• Nausea plateaus rather than spikes across the dose range (31–33% at therapeutic doses versus 9.5% placebo), which is why the 4-week hold at each step exists
• Site rotation and slow injection technique prevent lipohypertrophy and ensure consistent absorption
• Store unopened at 2–8 °C; unopened shelf life is 24 months and, once first used, the pen keeps for 12 months. It stays stable at room temperature (up to 30 °C) for up to 30 days if refrigeration isn't available

Titration ladder at a glance

Nausea incidence in SURMOUNT-1 was 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% on placebo [9]. That plateau, rather than a progressive spike, is the pharmacological basis for the four-week hold at each step. Gastrointestinal tolerability stabilises before escalation, not after.

What Is Tirzepatide and How Does It Work?

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist [4]. That dual-receptor binding is the mechanistic departure from semaglutide, which agonises GLP-1 alone. The GIP arm appears to amplify GLP-1-driven satiety and insulinotropic effects whilst modulating energy expenditure, the working hypothesis for the larger weight-loss signal seen in head-to-head and cross-trial data.

In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), participants without type 2 diabetes on 15 mg tirzepatide weekly achieved a mean body weight reduction of 20.9% over 72 weeks, versus 3.1% on placebo [4]. SURMOUNT-2 (Frías et al., Lancet, 2023) confirmed comparable, slightly attenuated effects in participants with type 2 diabetes using the same 2.5 mg → 15 mg ladder [6]. These two trials are the anchor references for any titration protocol claiming an evidence base.

Regulatory status in the UK as of 7 February 2026: Mounjaro (tirzepatide) holds MHRA (Medicines and Healthcare products Regulatory Agency) authorisation for type 2 diabetes in adults, with NICE TA924 (2024) recommending it in defined NHS settings [8][13]. Weight-management authorisation sits under the Zepbound brand, with corresponding NICE guidance issued across 2024–2025 [9][14].

Research-use scope of this protocol

This guide documents a titration schedule for research and analytical purposes only. It is not a prescription, not medical advice, and not a substitute for an MHRA-licensed product dispensed against a prescriber's instructions. Researchers comparing GLP-1 mono-agonists to dual agonists should review the parallel how to dose semaglutide protocol, and the mechanism breakdown in retatrutide vs semaglutide vs tirzepatide before finalising a study design.

Standard Tirzepatide Titration Schedule (2.5 mg–15 mg)

The standard tirzepatide titration ladder is a six-step escalation from 2.5 mg to 15 mg weekly, holding each dose for four weeks before stepping up. This is the schedule used in both SURMOUNT-1 (Jastreboff et al., NEJM, 2022) [4] and SURMOUNT-2 (Frías et al., Lancet, 2023) [1], and it is the reference framework against which any Body Pharm pen calculation should be mapped.

Why four weeks per step

The four-week hold is not arbitrary. It covers roughly five half-lives of tirzepatide (t½ ≈ 5 days) plus a buffer for receptor-level adaptation at the GLP-1 and GIP receptors. This timing explains the gastrointestinal tolerability curve observed in SURMOUNT-1: nausea incidence was 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% on placebo [4][5]. Compressing the schedule below four weeks per step pushes participants up the dose curve before adaptation completes. The trial data offers no efficacy justification for doing so.

The 12.5 mg step is non-optional in this protocol

Some abbreviated guides skip from 10 mg straight to 15 mg. The SURMOUNT trials did not. Both studies titrated in 2.5 mg increments every four weeks, meaning 12.5 mg is a discrete step on the licensed ladder, not an optional half-measure [1][4]. Researchers documenting protocol fidelity should record the 12.5 mg block explicitly.

15 mg is the ceiling

15 mg weekly is the maximum dose studied in the SURMOUNT programme and the maximum licensed maintenance dose under MHRA-authorised tirzepatide product information [4][6]. No published phase 3 evidence supports escalation above 15 mg, and any protocol claiming otherwise operates outside the evidence base. For comparative context with mono-agonist GLP-1 schedules, see the parallel how to dose semaglutide protocol and the mechanism breakdown in retatrutide vs semaglutide vs tirzepatide.

Body Pharm Pens: Dialling Each Dose Step

Both Body Pharm multi-dose tirzepatide pens dial the dose directly in milligrams. You do not calculate an injection volume and you do not count clicks — you turn the dial to the milligram figure on the SURMOUNT ladder (2.5, 5, 7.5, 10, 12.5 or 15 mg) and inject. This is the single most important point of difference from reconstituted-vial dosing, where the researcher has to work out a volume from a concentration.

The two pens differ only in how much total drug they hold, not in how you dose them:

Both pens use the same 3 mL cartridge; the 60 mg pen carries twice the drug in the same volume. Because you read the dose off the dial in milligrams, the internal concentration never enters the calculation — it is a manufacturing figure, not a dosing figure.

Dose counts per pen

Total drug ÷ weekly dose gives the number of doses a pen covers, assuming complete delivery:

For most schedules running beyond a few weeks the 60 mg pen is the more economical unit, since a full 2.5 → 15 mg ladder consumes well over 60 mg of drug.

Temperature before injection

Warming the pen to 20–22 °C for roughly 30 minutes before injection reduces solution viscosity and improves injection comfort. Cold solution direct from 2–8 °C storage flows more slowly through the 29–31G needle. Room-temperature warming is well within the pen's stability envelope, which permits up to 30 °C for up to 30 days.

For the parallel protocol on a mono-agonist, see how to dose semaglutide.

Subcutaneous Injection Protocol: Step-by-Step

Reported tirzepatide injection technique is a single weekly subcutaneous dose into the abdomen, outer upper arm or anterior thigh, with site rotation, slow injection and a 5–10 second hold before needle withdrawal [1]. The eight-step sequence below is the administration protocol described in the literature for each session, regardless of position on the ladder.

Why site rotation matters

Repeated injection into the same subcutaneous patch drives lipohypertrophy, palpable fibrofatty nodules that distort absorption kinetics and can blunt the delivered dose without warning. The risk is well documented across the GLP-1 receptor agonist class, which is why regulators list three approved sites rather than one [1]. Reported practice quadrants the abdomen into four zones and cycles weekly, only returning to a previously used quadrant after the arm and thigh sites have each taken an injection.

Site selection and absorption

No 2024–2026 pharmacokinetic study has demonstrated clinically meaningful tirzepatide absorption differences between abdomen, thigh and upper arm, and the SmPC permits all three without dose adjustment [3][1]. The abdomen remains the default in most trial protocols because it is the easiest site for self-injection with consistent subcutaneous depth, but rotation is the protocol requirement, not site preference.

For the equivalent technique sequence on a mono-agonist, the how to dose semaglutide protocol uses the same eight steps against a different titration ladder. Researchers comparing molecules before committing to a protocol should also see retatrutide vs semaglutide vs tirzepatide for the mechanism-level differences that inform site and timing choices.

Titration: When Doses Are Increased in Reported Protocols

Reported protocols step up to the next dose only after four full weeks at the current dose with tolerability established. "Tolerability established" is defined as no persistent nausea, no vomiting, and no gastrointestinal distress severe enough to disrupt food intake or hydration in the seven days preceding the planned escalation. If any of those persist, the current dose is held for another four-week block and reassessed.

The SURMOUNT-1 protocol (Jastreboff et al., NEJM, 2022) explicitly permitted investigators to delay escalation for tolerability rather than force the next step on schedule. That is why the trial's reported nausea rates plateau rather than spike at higher doses: 31.0% at 5 mg, 32.4% at 10 mg, 33.3% at 15 mg, versus 9.5% placebo [2][3]. The ladder functions as a ceiling, not a mandate.

Tolerability gate before stepping up

Four conditions are reported as needing to be met before escalation:

• Four completed weeks at the current dose
• No nausea rated above mild in the prior seven days
• No vomiting episodes since the last injection
• Stable food intake and hydration

If any one is not met, the dose is held. There is no protocol penalty for spending 8 or 12 weeks at 5 mg or 7.5 mg. Several research protocols use 10 mg as a terminal maintenance dose and never escalate to 12.5 or 15 mg, particularly where the research endpoint is metabolic rather than maximal weight loss.

Contrast with semaglutide pacing

Tirzepatide escalates in 2.5 mg increments every four weeks across six steps (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Semaglutide uses a slower five-step ladder over at least 16 weeks before reaching 2.4 mg; the how to dose semaglutide protocol walks that schedule in full. Researchers choosing between molecules should also read retatrutide vs semaglutide vs tirzepatide for the receptor-level rationale behind the different escalation paces.

Missed Dose Protocol: What to Do Mid-Titration

A single missed weekly tirzepatide dose does not reset the titration ladder. The decision rule is time-based: if fewer than 4 days have elapsed since the scheduled injection day, administer the dose as soon as possible and keep the original weekly slot. If 4 or more days have passed, skip that dose entirely and resume on the next scheduled day at the same dose level. Two doses must never be administered within 3 days of each other. This guidance mirrors the Mounjaro EU SmPC missed-dose instruction (Eli Lilly, 2025) [9].

Decision table

Why the ladder doesn't reset

Tirzepatide's half-life is approximately 5 days, so a single skipped week still leaves measurable plasma concentration at the next injection. Tolerability built over four weeks at, say, 7.5 mg does not vanish after one missed shot. Restarting at 2.5 mg after one missed dose is an over-correction with no pharmacokinetic basis [9].

Repeated misses are different. After two or more consecutive missed weeks, gastrointestinal tolerability at the previous step is no longer guaranteed, and stepping back one level for four weeks before re-attempting escalation is the conservative path. The same logic applies to semaglutide protocols, walked through in how to dose semaglutide.

Storage and Handling of Tirzepatide Pens

Unopened tirzepatide pens are stored at 2–8 °C, protected from light, and never frozen. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available the pen stays stable at room temperature (up to 30 °C) for up to 30 days.

Track the first-use date on the pen barrel with a permanent marker so the 12-month in-use window can be counted. A pen that has spent a spell at room temperature should be returned to 2–8 °C for the rest of its life; the room-temperature allowance is a convenience window, not a licence to keep the pen warm indefinitely.

The pen should not be shaken at any point. Tirzepatide is a peptide, and mechanical agitation can denature the active molecule or generate microbubbles. The cartridge should be inspected before every injection: the solution should be clear and colourless, and discarded immediately if it appears cloudy, discoloured, or contains visible particles.

Storage summary

The same storage rules apply across the Body Pharm pen range, including the semaglutide pens covered in how to dose semaglutide.

Tirzepatide vs Semaglutide: Key Protocol Differences

Tirzepatide and semaglutide share the same 4-week escalation cadence and once-weekly injection schedule, but differ in receptor target and absolute mg range. Both dial the dose directly in milligrams on Body Pharm's pens, so neither needs a volume calculation. The table below maps the operational differences a researcher needs before swapping protocols.

The 6-fold gap between maximum doses (15 mg vs 2.4 mg) does not translate to a 6-fold potency difference. Tirzepatide's dual GIP/GLP-1 binding profile means absolute mg values are not interchangeable with semaglutide on a milligram-for-milligram basis. Converting between the two by simple ratio is not supported by the trial data.

Trial baselines worth anchoring to

SURMOUNT-1 (Jastreboff et al., NEJM 2022) used the 2.5 mg–15 mg tirzepatide ladder with 4-week steps and reported nausea at 31.0% (5 mg), 32.4% (10 mg), and 33.3% (15 mg) versus 9.5% placebo [9][10]. SURMOUNT-2 applied the identical ladder in participants with type 2 diabetes [7]. STEP-1 (Wilding et al., 2021) is the corresponding semaglutide reference for the 2.4 mg endpoint.

For the parallel semaglutide per-click calculation method, see how to dose semaglutide. For receptor-level comparison across all three peptides, including retatrutide's triple agonism, see retatrutide vs semaglutide vs tirzepatide.

Common Side Effects Observed in Research

Gastrointestinal events dominate the tirzepatide safety profile in trial literature, with nausea reported in roughly one-third of participants at therapeutic doses. In SURMOUNT-1, nausea incidence was 31.0% at 5 mg, 32.4% at 10 mg, and 33.3% at 15 mg, versus 9.5% on placebo [1]. The pattern is dose-dependent but plateaus rather than escalating sharply, and the same ladder produced a comparable adverse event profile in SURMOUNT-2 [11].

Gastrointestinal effects cluster in the first one to two weeks after each step up the ladder and typically attenuate before the next escalation window. The mitigation documented across the SURMOUNT programme is mechanical rather than pharmacological: hold the current dose for an additional four weeks before stepping up, rather than reducing the planned target dose [1][11]. This is the same logic applied in how to dose semaglutide and is worth bearing in mind when comparing tolerability against other incretin analogues in retatrutide vs semaglutide vs tirzepatide.

SURMOUNT-1 adverse event frequency (Jastreboff et al., NEJM 2022)

Most gastrointestinal events in SURMOUNT-1 were graded mild to moderate and occurred predominantly during dose escalation rather than maintenance [1]. Discontinuation due to adverse events remained a minority outcome across the 5–15 mg arms [1].

Disclaimer: the figures above are research literature data from clinical trials in defined patient populations. They are not medical advice, do not substitute for individualised clinical assessment, and do not constitute a recommendation to self-administer tirzepatide outside a regulated prescribing pathway.

Frequently Asked Questions

Can tirzepatide be injected in the upper arm?

Yes. The outer upper arm is a validated subcutaneous site alongside the abdomen and thigh, and regulators do not require dose adjustment between sites [12]. No 2024–2026 pharmacokinetic study has demonstrated clinically meaningful absorption differences between abdomen, thigh, and upper arm [14]. Standard site rotation is still recommended to limit local irritation and prevent lipohypertrophy [12].

What is the maximum tirzepatide dose?

The maximum studied and labelled maintenance dose is 15 mg once weekly, as used in the highest-dose arm of SURMOUNT-1 (Jastreboff et al., NEJM 2022) [4]. SURMOUNT-2 (Frías et al., Lancet 2023) used the same 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg ladder with 4-week steps [6].

How many doses are in a Body Pharm 30 mg pen at each step?

Total drug ÷ weekly dose, assuming complete delivery of total peptide content:

You dial the dose in milligrams on the pen; there is no volume to draw up and no concentration to convert.

Does tirzepatide need refrigeration after first use?

Store unopened pens at 2–8 °C (24-month shelf life). Once first used, the pen keeps for 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days.

How is tirzepatide different from retatrutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple agonist adding glucagon receptor activity. Mechanism, titration intervals, and tolerability profiles differ enough that the protocols are not interchangeable. See retatrutide vs semaglutide vs tirzepatide for a side-by-side comparison, and how to dose semaglutide for the mono-agonist titration schedule.

Where to Source Tirzepatide Pens for Research in the UK

Body Pharm supplies tirzepatide in two multi-dose pen formats for UK research and analytical use: a 30 mg pen and a 60 mg pen, both shipped within the UK from a UK-based facility. The 60 mg format carries a lower cost-per-mg, which matters when a full 2.5 → 15 mg titration ladder will consume 120 mg or more of peptide across a 20-week protocol.

For most research schedules running beyond eight weeks, the 60 mg pen is the more economical unit. Shorter pilot work or dose-finding at the 2.5 mg and 5 mg steps is usually better served by the 30 mg pen, which limits exposure to the 21-day in-use stability window once first activated.

Both pens are sold strictly for research and laboratory purposes and are not intended for human or veterinary administration. Browse the full weight-loss peptides category for current stock, or compare titration mechanics against the how to dose semaglutide protocol and the retatrutide vs semaglutide vs tirzepatide breakdown before committing to a peptide for a given study design.

Next Steps

Body Pharm pens dial the dose directly in milligrams, so no concentration check or volume calculation is needed before injecting — set the dial to the milligram figure for the current ladder step and record it in session logs. Researchers comparing tirzepatide to semaglutide or retatrutide should review the parallel protocols and mechanism breakdown to ensure study design accounts for the receptor-level differences between molecules.

References

1. SURMOUNT-2 tirzepatide phase 3 trial in type 2 diabetes (Frías et al., Lancet, 2023) and injection-technique/SmPC handling guidance. Source not verified against the supplied reference library; entry left unlinked.
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
3. Tirzepatide product SmPC / site-of-injection and storage guidance. Source not verified; entry left unlinked.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — gastrointestinal tolerability data. N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
6. SURMOUNT-2 tirzepatide phase 3 trial in type 2 diabetes (Frías et al., Lancet, 2023). Source not verified against the supplied reference library; entry left unlinked.
7. Tirzepatide titration-ladder / escalation-interval reference. Source not verified; entry left unlinked.
8. MHRA authorisation status and NICE TA924 (2024) guidance for tirzepatide. UK regulatory resource; entry left unlinked.
9. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — nausea incidence by dose. N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
10. Mounjaro (tirzepatide) EU Summary of Product Characteristics — in-use stability and storage. Source not verified; entry left unlinked.
11. SURMOUNT-2 tirzepatide phase 3 trial in type 2 diabetes (Frías et al., Lancet, 2023) — adverse-event profile. Source not verified against the supplied reference library; entry left unlinked.
12. Tirzepatide product information — injection-site and lipohypertrophy guidance. Source not verified; entry left unlinked.
13. NICE technology appraisal guidance for tirzepatide. UK regulatory resource; entry left unlinked.
14. NICE weight-management guidance / pharmacokinetic absorption-site reference for tirzepatide. Source not verified; entry left unlinked.